Sage Therapeutics, Inc. (SAGE)

NASDAQ: SAGE · IEX Real-Time Price · USD
38.56
+0.89 (2.36%)
At close: Sep 27, 2022 4:00 PM
37.40
-1.16 (-3.01%)
After-hours: Sep 27, 2022 4:06 PM EDT
2.36%
Market Cap 2.29B
Revenue (ttm) 6.17M
Net Income (ttm) -503.20M
Shares Out 59.42M
EPS (ttm) -8.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 233,036
Open 38.42
Previous Close 37.67
Day's Range 37.96 - 39.48
52-Week Range 27.36 - 47.75
Beta 1.37
Analysts Buy
Price Target 60.28 (+56.3%)
Earnings Date Oct 31, 2022

About SAGE

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compoun... [Read more...]

Industry Biotechnology
IPO Date Jul 18, 2014
CEO Jeffrey Jonas
Employees 471
Stock Exchange NASDAQ
Ticker Symbol SAGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 28 analysts, the average rating for SAGE stock is "Buy." The 12-month stock price forecast is 60.28, which is an increase of 56.33% from the latest price.

Price Target
$60.28
(56.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zur...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new analyses from across the development program for zuranolone, an investigation...

Other symbols: BIIB
1 week ago - Business Wire

Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will p...

3 weeks ago - Business Wire

Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Other symbols: BIIB
1 month ago - Investors Business Daily

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.39% and 14.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business...

1 month ago - Business Wire

Sage Therapeutics to Present at Upcoming August Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will p...

1 month ago - Business Wire

Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it...

2 months ago - Business Wire

Why Shares of Sage Therapeutics Climbed 15.6% This Week

Investors can see the finish line for the company's second marketed therapy.

3 months ago - The Motley Fool

Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.

Other symbols: BIIB
3 months ago - Zacks Investment Research

Sage Therapeutics to Present at Upcoming June Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will p...

3 months ago - Business Wire

Sage Stock Rises on Postpartum Depression Drug Data

Biogen and Sage Therapeutics said new data allows them to seek approval for their depression medication zuranolone as a treatment for postpartum depression early next year.

3 months ago - Barrons

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its P...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the Phase 3 SKYLARK Study of zuranolone, an investigational oral drug being ...

Other symbols: BIIB
3 months ago - Business Wire

Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will g...

4 months ago - Business Wire

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Lags Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 0.96% and 66.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and ...

4 months ago - Business Wire

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administ...

Other symbols: BIIB
4 months ago - Business Wire

Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a liv...

5 months ago - Business Wire

Strength Seen in Sage Therapeutics, Inc. (SAGE): Can Its 11.8% Jump Turn into More Strength?

Sage Therapeutics, Inc. (SAGE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...

5 months ago - Zacks Investment Research

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today the presentation of dat...

5 months ago - Business Wire

Sage Therapeutics to Present at 2022 Stifel CNS Days

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will g...

6 months ago - Business Wire

Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today the presentation of dat...

6 months ago - Business Wire

Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

6 months ago - Business Wire

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Misses Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company fearlessly leading the way to create a world with better brain health, today reported business high...

7 months ago - Business Wire

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research